학술논문
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
Document Type
article
Author
Luca Licata; Giulia Viale; Mario Giuliano; Giuseppe Curigliano; Mariana Chavez-MacGregor; Julia Foldi; Oluchi Oke; Joseph Collins; Lucia Del Mastro; Fabio Puglisi; Filippo Montemurro; Claudio Vernieri; Lorenzo Gerratana; Sara Giordano; Alessia Rognone; Lorenzo Sica; Oreste Davide Gentilini; Stefano Cascinu; Lajos Pusztai; Antonio Giordano; Carmen Criscitiello; Giampaolo Bianchini
Source
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Subject
Language
English
ISSN
2374-4677
Abstract
Abstract Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we aim to evaluate whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations. We randomly select 30 patients with ER+/HER2− eBC and recurrence score (RS) available from an institutional database. We ask 16 breast oncologists with varying years of clinical practice in Italy and the US to provide recommendation for the addition of chemotherapy to endocrine therapy and their degree of confidence in the recommendation twice; first, based on clinicopathologic features only (pre-RS), and then with RS result (post-RS). Pre-RS, the average rate of chemotherapy recommendation is 50.8% and is higher among junior (62% vs 44%; p